MARÍA CRISTINA
CHURRUCA GALAZ
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (2)
2024
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621